Keytruda in Nepal
How patients in Nepal access Keytruda (PD‑1 inhibitor) via Named Patient Program.
Keytruda - overview
Keytruda (PD‑1 inhibitor) is manufactured by Merck (MSD) and indicated for multiple oncology indications including melanoma, NSCLC, head and neck cancer, classical Hodgkin lymphoma, urothelial carcinoma, MSI-H/dMMR solid tumors, TMB-H solid tumors, renal cell carcinoma, endometrial carcinoma, triple-negative breast cancer, cervical cancer, gastric cancer, and others, see full prescribing information. It is an intravenous anti-PD-1 monoclonal antibody approved by the US FDA in 2014 and may be accessible to patients in Nepal through a Named Patient Program or personal-import pathway.
Access in Nepal
Nepal's DDA has a personal-use pathway; volumes are small but process exists.
How Reserve Meds coordinates access in Nepal
- Patient or treating physician submits a request.
- We verify clinical appropriateness and Nepal-specific eligibility.
- Treating physician in Nepal issues prescription and clinical justification.
- Country-specific NPP/personal-import forms are prepared and filed.
- We source Keytruda from a DSCSA-compliant US specialty wholesaler.
- Cold-chain shipment to the patient's physician or hospital pharmacy in Nepal.
Typical timeline for Nepal
End-to-end, most requests are completed in 2-6 weeks. Nepal's tier 3 regulatory maturity typically supports longer processing times.
What patients and physicians in Nepal ask
- Is the pathway legal in Nepal? Yes - it operates under Nepal's established NPP or personal-import framework.
- Does my insurance cover it? Typically no for NPP drugs; patient prepayment is standard.
- What physician credentials do I need? A licensed physician in Nepal able to issue the prescription and clinical justification.
- What if the drug is in shortage? We will inform you upfront and decline rather than promise what we cannot deliver.
- Can I re-supply? Yes - for chronic therapies we arrange ongoing re-supply.